Synergy Pharmaceuticals, Inc.
420 Lexington Avenue
Suite 1609
New York,
NY 10170
United States - Map
Phone: 212-297-0020
Fax: 212-297-0019
Website: http://www.synergypharma.com
| Index Membership: | N/A | | Sector: | Healthcare | | Industry: | Drug Manufacturers - Other | | Full Time Employees: | 18 |
|
Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development of drugs to treat gastrointestinal (GI) disorders and diseases. Its lead product candidate includes plecanatide, a guanylyl cyclase C receptor agonist that has completed Phase IIa clinical trials to treat chronic idiopathic constipation GI disorders, as well as is in Phase IIb clinical trials for the treatment of constipation-predominant irritable bowel syndrome GI disorders. The company also develops SP-333, which is in Phase I clinical trials to treat GI inflammatory diseases, such as ulcerative colitis. Synergy Pharmaceuticals Inc. is headquartered in New York, New York. Key Statistics
| |
| | Pay | Exercised | Dr. Gary S. Jacob Ph.D.,
66
Chief Exec. Officer, Pres and Director | 562.00K | 0.00 | Mr. Bernard F. Denoyer CPA, M.B.A.,
65
Principal Financial Officer, Principal Accounting Officer, Sr. VP of Fin. and Sec. | 246.00K | 0.00 | Dr. Kunwar Shailubhai Ph.D.,
55
Chief Scientific Officer | 317.00K | 0.00 | Dr. Laura Barrow Pharm. D.,
Sr. VP of Clinical Operations | N/A | N/A | Dr. Patrick H. Griffin M.D., FACP,
Chief Medical Officer | N/A | N/A |
|
| | Amounts are as of Dec 31, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year. | | Currency in USD. |
|
1.45%